Evaluation of mucosal barrier disruption due to Staphylococcus lugdunensis and Staphylococcus epidermidis exoproteins in patients with chronic rhinosinusitis
International Forum of Allergy & Rhinology · 2025
DOI: 10.1002/alr.23481 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Mahnaz Ramezanpour und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery-Otolaryngology, Head and Neck Surgery, Central Adelaide Local Health Network (Basil Hetzel Institute), The Queen Elizabeth Hosp…. Hauptthemen laut MEDLINE: Staphylococcus epidermidis, Sinusitis, Rhinitis, Nasal Mucosa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Chronic rhinosinusitis (CRS) is a persistent inflammatory condition of the sinus mucosa. While Staphylococcus aureus has been shown to play a significant role in mucosal barrier disruption in CRS patients, coagulase‐negative staphylococci (CoNS) such as Staphylococcus epidermidis and Staphylococcus lugdunensis are also implicated in CRS pathophysiology. This study investigates the effects of exoproteins secreted by planktonic and biofilm forms of clinical isolates of S. epidermidis and S. lugdunensis on the nasal epithelial barrier.
Methods
Thirty‐one clinical isolates of CoNS were grown in planktonic and biofilm forms, and their exoproteins were concentrated. The epithelial barrier structure was assessed by measuring transepithelial electrical resistance (TEER) and the permeability of fluorescein isothiocyanate‐dextran. Toxicity and inflammatory response were also studied.
Results
Our findings demonstrate that exoproteins from all planktonic forms of S. lugdunensis disrupted the mucosal barrier, whereas only nine of 16 biofilm‐derived exoproteins had similar effects. Conversely, 11 of 15 exoproteins from planktonic S. epidermidis significantly disrupted barrier integrity; however, biofilm exoproteins did not. The study also showed that some exoproteins from planktonic S. epidermidis significantly reduced cell viability, while exoproteins from planktonic and biofilm forms of S. lugdunensis and biofilm S. epidermidis did not induce any statistically significant change in cell viability. Notably, four of 16 biofilm exoproteins from S. lugdunensis induced higher interleukin‐6 (IL‐6) secretion, whereas none of the S. epidermidis isolates showed a significant increase in IL‐6 secretion.
Conclusion
Our results suggest that CoNS exoproteins may contribute to CRS etiopathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery-Otolaryngology, Head and Neck Surgery, Central Adelaide Local Health Network (Basil Hetzel Institute), The Queen Elizabeth Hospital, University of Adelaide, Adelaide, South Australia, Australia.
- Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
ORCID-Profile: Mahnaz Ramezanpour, Sholeh Feizi
Zitieren
APA
Ramezanpour, M., Feizi, S., Arachchige, H. D. P., Bouras, G., Cooksley, C., Shaghayegh, G., Wormald, P. J., Psaltis, A. J., & Vreugde, S. (2025). Evaluation of mucosal barrier disruption due to Staphylococcus lugdunensis and Staphylococcus epidermidis exoproteins in patients with chronic rhinosinusitis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23481
Vancouver
Ramezanpour M, Feizi S, Arachchige HDP, Bouras G, Cooksley C, Shaghayegh G, et al. Evaluation of mucosal barrier disruption due to Staphylococcus lugdunensis and Staphylococcus epidermidis exoproteins in patients with chronic rhinosinusitis. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23481
BibTeX
@article{Ramezanpour2025,
author = {Ramezanpour, Mahnaz and Feizi, Sholeh and Arachchige, Hashan Dilendra Paththini and Bouras, George and Cooksley, Clare and Shaghayegh, Gohar and Wormald, Peter-John and Psaltis, Alkis James and Vreugde, Sarah},
title = {Evaluation of mucosal barrier disruption due to Staphylococcus lugdunensis and Staphylococcus epidermidis exoproteins in patients with chronic rhinosinusitis},
journal = {International Forum of Allergy & Rhinology},
year = {2025},
doi = {10.1002/alr.23481}
}
EUVIMED